Subgroup analysis wasn’t accomplished regarding the association of KIR-HLA combinations and HLA-I ligands with different lung cancer subtypes owing to the inadequate sample size included in the HLA typing method. This evidence concerns the gene KIR3DL1 and lung cancer.